恩格列净对老年2型糖尿病患者骨代谢和骨密度的影响  

Effects of empagliflozin on bone metabolism and bone mineral density in elderly patients with type 2 diabetes

作　　者：王妍 杨玲[1] 杨佳苗 刘连勇[1] 郑超[1] Wang Yan;Yang Ling;Yang Jiamiao;Liu Lianyong;Zheng Chao(Department of Endocrinology,Punan Hospital of Pudong New District,Shanghai,P.R.China,200125)

机构地区：[1]上海市浦东新区浦南医院内分泌科,上海200125

出　　处：《老年医学与保健》2023年第1期86-90,共5页Geriatrics & Health Care

基　　金：上海市浦东新区卫生科技面上项目(PW2020A-76);上海市浦东新区重点学科项目(PWZxk2022-29)。

摘　　要：目的探索恩格列净对老年2型糖尿病(T2DM)患者除了糖代谢方面,是否对骨代谢也有额外的风险,为伴随高骨折风险的T2DM患者的降糖方案提供循证依据。方法选取自2020年1月—2021年12月浦南医院内分泌科诊疗的T2DM患者,随机分为干预组(恩格列净组)及对照组(维持原来的内分泌降糖治疗)2组,收集2组患者的一般情况、血糖、骨密度及骨代谢指标资料,分析T2DM患者应用恩格列净后骨形成指标、骨吸收指标及骨密度水平的变化情况。结果与对照组相比,恩格列净组患者的体质量、体质量指数(BMI)显著低于对照组(P<0.05),血糖指标2组呈相似水平,无显著统计学差异。2组患者骨密度及骨代谢指标均差异无统计学意义。结论T2DM患者应用恩格列净可显著降低体质量及BMI,对骨代谢指标及骨密度无明显影响。Objective To explore whether empagliflozin has additional risks to bone metabolism in addition to glucose metabolism in elderly patients with type 2 diabetes mellitus(T2DM),so as to provide evidence-based evidence for hypoglycemic regimen in T2DM patients with high fracture risk.Methods T2DM patients who were diagnosed and treated in Department of Endocrinology of Punan Hospital from January 2020 to December 2021 were randomly divided into two groups:intervention group(empagliflozin group)and control group(maintaining the original endocrine hypoglycemic medications).The general information,blood glucose,bone mineral density and bone metabolism indexes of the two groups were collected.The changes of bone formation indexes,bone resorption indexes and bone mineral density level in T2DM patients were analyzed after treatment with empagliflozin.Results The body weight and body mass index(BMI)of the intervention group were significantly lower than those of the control group(P<0.05).The levels of blood glucose indexes of the two groups were similar,with no significant statistical difference.There was no significant difference in the bone mineral density indexes and bone metabolism between the two groups.Conclusion Empagliflozin can significantly reduce body weight and BMI in T2DM patients,but has no significant effects on bone metabolic indexes and bone mineral density.

关 键 词：老年 2型糖尿病 恩格列净 骨代谢 骨密度 

分 类 号：R587.1[医药卫生—内分泌]